<DOC>
	<DOCNO>NCT01835730</DOCNO>
	<brief_summary>This study first-in-human randomize , double-blind ( Investigator subject ) , placebo control single ascending dose study enroll approximately 40 ( 6 active/2 placebo per dose group ) adult male female subject Type 2 Diabetes Mellitus ( T2DM ) .</brief_summary>
	<brief_title>Phase 1 Multicenter , Single Ascending Dose Study Assess Safety , Tolerability , Pharmacokinetic Pharmacodynamic Response PE0139 Injection Adult Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Willing able sign write informed consent follow studyrelated procedure ; Male female subject least 18 year age ; Male subject female subject childbearing potential must practice effective contraception study willing able continue contraception 30 day dose study drug ; Body mass index ≤45 kg/m2 ; Diagnosed T2DM currently take stable daily dose basal insulin ( Lantus ) plus least one oral antihyperglycemic agent stable dose 3 month prior screen . Currently take take within 3 month prior screen approve investigational GLP1 analogue/agonist ( e.g. , Victoza® ) pramlintide ; Currently take routinely take , within 3 month prior screen , shortacting insulin ; Currently take take , within 3 month prior screen , long act insulin Lantus® ; Known allergy , serious adverse effect cause approve , investigational insulin product component ; Currently take follow medication : thiazide furosemide diuretic , betablockers , estrogens hormonal replacement therapy , chronic medication know adverse effect glucose tolerance level unless subject stable dos agent least 2 month prior screen plan change study period ; History recurrent severe hypoglycemia ( 2 episode within last 6 month prior randomization hypoglycemic unawareness ; Malignant disease define 1 ) history malignant melanoma breast cancer and/or 2 ) history type cancer within last 5 year prior screen ; Unstable cardiovascular disease define one following : History stroke , transient ischemic attack , myocardial infarction within 6 month prior screen ; History currently New York Heart Association Class IIIIV heart failure prior screening ; Uncontrolled/sustained hypertension ; History evidence long QT syndrome mean triplicate 12lead electrocardiogram demonstrate QT interval ; Clinically significant renal and/or hepatic dysfunction ; Absolute requirement corticosteroid receive systemic steroid within 3 month prior Randomization ( V5 , Day 1 ) . Note : Use inhale topical corticosteroid permit ; Pregnant lactate female subject ; Known history active alcohol abuse use illicit drug within 1 year prior screening ; Positive screen human immunodeficiency virus antibody , hepatitis B surface antigen , hepatitis C virus antibody V1 ; Participating study receive investigational medication device within 30 day prior Visit 1 . Other medical psychiatric condition , opinion Investigator , would place subject increase risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>